INFLUENZA A VIRUS IN SWINE (IAV-S)
LEVELS: Highly unlikely: No controls necessary; Occupational exposure risk: Non-foodborne transmission pathway(s) that are strongly associated with occupational exposure and can lead to human infection; Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent; Not feasible: Eradication extremely unlikely
OVERVIEW
Influenza A virus in swine (IAV-S) is an orthomyxovirus and a major cause of acute respiratory disease in pigs worldwide. The association between swine and human influenza dates to the 1918 pandemic, when influenza-like disease appeared concurrently in pigs and humans in both the United States and Europe. IAV-S exists as multiple subtypes (primarily H1N1, H1N2, H3N2) and numerous genetic lineages that vary by geographic region—North American triple reassortant lineages, European avian-like H1N1 and human-derived lineages, and complex Asian reassortants. The segmented RNA genome enables genetic reassortment when two viruses coinfect a single host, generating novel genotypes with pandemic potential. The 2009 H1N1 pandemic virus arose through reassortment between North American and Eurasian swine lineages before spreading globally through humans. Pigs are postulated to serve as "mixing vessels" for influenza virus evolution due to their susceptibility to both avian and human influenza viruses. Human-to-swine transmission occurs frequently and continuously seeds swine populations with new viral diversity. IAV-S causes high morbidity (up to 100%) but low mortality (<1%) in uncomplicated infections, with rapid recovery typically within 5-7 days. The virus is endemic in pig populations globally, with seasonal epidemic peaks. Multiple commercial vaccines are available but strain diversity creates ongoing challenges for antigenic matching between vaccines and circulating field strains.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
IAV-S does not pose a food safety risk. The chapter explicitly states that "IAV-S is not a food safety or pork trade concern." Virus replication is strictly limited to the respiratory tract epithelium—nasal mucosa, trachea, and lungs. Pig infection studies with H1N1pdm09 confirmed the absence of virus in pork and muscle tissue. IAV-S has never been detected in meat products, and no foodborne transmission to humans has been documented. The virus spreads exclusively via the respiratory route through infectious oronasal secretions and aerosols. Consumption of properly handled pork products poses no influenza transmission risk.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Occupational exposure risk: Non-foodborne transmission pathway(s) that are strongly associated with occupational exposure and can lead to human infection
Human infections with swine IAV are well-documented, particularly in people with occupational exposure to pigs. Cases have been reported primarily in the United States with H3N2, H1N2, and H1N1 viruses of North American triple reassortant lineages, with increasing detections in recent years from South America, Europe, Australia, and Asia. Agricultural fairs where pigs and humans have close contact are recognized transmission settings. Studies of swine workers suggest IAV-S infections may be underdiagnosed. However, sustained person-to-person transmission of swine-lineage viruses is rare—most human cases remain isolated events without secondary spread. The notable exception is the 2009 H1N1 pandemic, which arose from swine virus reassortment and subsequently achieved efficient human-to-human transmission. Pigs harbor older human-origin HA genes against which younger human birth cohorts lack immunity, creating theoretical pandemic risk if such viruses readapt to efficient human transmission.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Unlikely to be effective: One or more pathways of farm-to-farm transmission exist that cannot be controlled by on-farm biosecurity
IAV-S is introduced to herds primarily through movement of infected animals, with transmission via direct contact with infectious oronasal secretions containing up to 10⁷ infectious particles per mL at peak shedding. However, aerosol detection during natural outbreaks demonstrates significant airborne virus in swine barns, contributing to within-barn spread and representing exposure risk to humans. Aerosol transmission may explain IAV-S infections on farms with high biosecurity. In breeding herds, virus is frequently detected in replacement gilts and suckling piglets, with nurse sows contributing to pre-weaning transmission. On farrow-to-finish operations, continuous introduction of susceptible young pigs with declining maternal immunity enables viral persistence. Standard biosecurity measures (controlled animal movement, sanitation, ventilation management) reduce but do not eliminate transmission risk. The virus does not have wildlife reservoirs that independently maintain swine-adapted strains, distinguishing it from diseases like pseudorabies where feral swine complicate control.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
Clinical presentation of IAV-S—acute respiratory disease with high fever, anorexia, tachypnea, coughing, and labored breathing—overlaps with other respiratory pathogens in the porcine respiratory disease complex (PRDC). No pathognomonic signs exist. Gross lesions (viral pneumonia with consolidation of cranioventral lung lobes) and microscopic findings (epithelial necrosis, neutrophilic airway infiltration) are suggestive but not specific. Laboratory confirmation is required and well-established: RT-PCR assays (pan-influenza A for screening, subtype-specific for characterization) provide rapid, sensitive detection from nasal swabs, oral fluids, or tissues collected during the febrile period. Virus isolation in MDCK cells confirms viable virus. Serology (HI test, ELISA, VN) demonstrates antibody responses but interpretation is complicated by co-circulation of multiple subtypes and cross-reactivity between strains. Acute and convalescent paired sera are needed for diagnosis of active infection. The diversity of circulating lineages requires that diagnostic reagents be regularly updated to maintain sensitivity.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals
IAV-S is endemic globally, causing ongoing production losses through direct disease effects and contribution to PRDC. Typical outbreaks produce high morbidity (up to 100%) with clinical signs lasting 5-7 days before recovery. Direct losses include reduced feed intake and weight loss during acute illness, increased days to market weight, medication costs for secondary bacterial infections, and occasional mortality (<1% in uncomplicated cases but higher with bacterial co-infection). IAV-S is one of the most frequently detected pathogens in 10-22 week old pigs with PRDC, along with PRRSV and Mycoplasma hyopneumoniae. Dual infections with these pathogens produce more severe disease than IAV-S alone. Reproductive impacts (reduced performance, abortion, weak litters) are reported anecdotally but not well-documented—little evidence suggests IAV directly infects the reproductive tract. Seasonal epidemic peaks (October-November primary, March-April secondary in the US) create predictable periods of elevated losses. Endemic circulation with continuous introduction of new genetic variants through human-to-swine spillover ensures IAV-S remains a persistent production challenge.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
IAV-S is not an OIE/WOAH-listed disease for trade purposes. The virus is endemic in pig populations on every continent with significant swine production, eliminating any basis for trade discrimination between major trading partners. The chapter explicitly states IAV-S "is not a food safety or pork trade concern" given the absence of virus in muscle tissue and lack of foodborne transmission. Detection of IAV-S in a herd does not trigger regulatory notification, movement restrictions, or trade consequences. Consumer awareness of "swine flu" relates to human pandemic risk rather than pork safety—the 2009 pandemic briefly affected pork consumption due to public misunderstanding, but this was a communication issue rather than a genuine food safety concern. Market impacts are limited to endemic production losses rather than acute trade disruption.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
IAV-S is a viral pathogen (negative-sense RNA virus) that does not carry, acquire, or transmit antimicrobial resistance genes. The virus poses no AMR concerns. However, IAV-S does undergo continuous antigenic evolution through genetic drift (point mutations) and shift (reassortment), creating challenges for vaccine strain matching. This represents antigenic escape from immunity rather than antimicrobial resistance.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments are used for IAV-S in commercial pig production. While neuraminidase inhibitors (oseltamivir, zanamivir) are effective against influenza in humans, they are not approved, practical, or economically feasible for swine. Disease management relies on vaccination, biosecurity, and management practices rather than therapeutic intervention. Antimicrobials may be used to treat secondary bacterial pneumonia following IAV-S infection, representing a minor, episodic use pattern that does not constitute a major driver of AMR selection pressure. The primary management strategy is prevention through vaccination and herd immunity rather than treatment of clinical cases.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific antiviral treatments are available or practical for IAV-S in commercial swine production. Management of clinical cases is limited to supportive care and treatment of secondary bacterial infections with appropriate antimicrobials. Neuraminidase inhibitors used in human influenza are not approved for swine use and would be impractical given the scale of commercial pig production, rapid disease course, and need for early administration. Recovery from uncomplicated IAV-S infection occurs within 5-7 days regardless of intervention, driven by the host immune response. The absence of effective therapeutics places emphasis entirely on prevention through vaccination and biosecurity.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent
Multiple commercial IAV-S vaccines are available in North America and Europe, primarily inactivated whole virus formulations with adjuvant administered intramuscularly. These vaccines effectively induce serum HI and VN antibodies that reduce lung virus titers and prevent clinical disease when vaccine strains closely match circulating field strains. However, significant limitations exist:
Strain matching challenges: The diversity of IAV-S lineages means no single vaccine provides universal coverage. Vaccines contain region-specific strains, and even within a region, antigenic drift creates mismatches. The lack of a formal strain recommendation system (unlike human influenza vaccines) complicates selection.
Autogenous vaccines: Custom-made vaccines from farm-specific isolates are widely used in the US (possibly the majority of vaccines used) to address strain matching, but quality and efficacy vary.
Maternal antibody interference: Prolonged passive immunity from vaccinated sows interferes with effective piglet vaccination, creating a window of susceptibility.
Limited mucosal immunity: Parenteral inactivated vaccines do not efficiently induce mucosal IgA or CD8+ T cell responses, providing less protection against upper airway shedding and transmission than against lung disease.
LAIV withdrawal: A live attenuated intranasal vaccine was withdrawn from the US market in 2020 after reassortant viruses combining LAIV and endemic strain genes were detected in the field.
Newer technologies include replicon particle (RP) vaccines expressing HA or NA antigens, with an NA-based vaccine licensed in 2022 that may overcome some maternal antibody interference issues.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Not feasible: Eradication extremely unlikely
Eradication of IAV-S from US swine populations is not feasible for multiple reasons:
Global endemicity: IAV-S circulates in pig populations on every continent. Eliminating the virus from US pigs would require either permanent isolation from global swine trade or simultaneous global eradication—neither is practical.
Continuous human-to-swine spillover: Human seasonal influenza viruses repeatedly transmit to pigs, seeding new lineages. This ongoing introduction pathway cannot be controlled through swine-focused interventions.
No DIVA capability: Unlike pseudorabies, there is no marker vaccine system enabling serological differentiation of vaccinated from infected animals, making test-and-removal programs impractical.
Rapid evolution: The segmented genome enables reassortment that continuously generates new genotypes, and antigenic drift produces ongoing variation within lineages.
Endemic equilibrium: IAV-S has established stable endemic circulation with seasonal patterns, widespread herd immunity, and maternal antibody transfer—an ecological state that resists elimination.
Management focuses on reducing clinical impact through vaccination, optimizing herd immunity, and implementing biosecurity to limit introduction of new variants, rather than pursuing elimination.